{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:26:06Z","timestamp":1790616366965,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a lymphoid neoplasm characterized by the accumulation of mature B cells. The diagnosis is established by the detection of monoclonal B lymphocytes in peripheral blood, even in early stages [monoclonal B-cell lymphocytosis (MBL<jats:sup>hi<\/jats:sup>)], and its clinical course is highly heterogeneous. In fact, there are well-characterized multiple prognostic factors that are also related to the observed genetic heterogenicity, such as immunoglobulin heavy chain variable region (IGHV) mutational status, del17p, and<jats:italic>TP53<\/jats:italic>mutations, among others. Moreover, a dysregulation of the immune system (innate and adaptive immunity) has been observed in CLL patients, with strong impact on immune surveillance and consequently on the onset, evolution, and therapy response. In addition, the tumor microenvironment is highly complex and heterogeneous (i.e., matrix, fibroblast, endothelial cells, and immune cells), playing a critical role in the evolution of CLL. In this study, a quantitative profile of 103 proteins (cytokines, chemokines, growth\/regulatory factors, immune checkpoints, and soluble receptors) in 67 serum samples (57 CLL and 10 MBL<jats:sup>hi<\/jats:sup>) has been systematically evaluated. Also, differential profiles of soluble immune factors that discriminate between MBL<jats:sup>hi<\/jats:sup>and CLL (sCD47, sCD27, sTIMD-4, sIL-2R, and sULBP-1), disease progression (sCD48, sCD27, sArginase-1, sLAG-3, IL-4, and sIL-2R), or among profiles correlated with other prognostic factors, such as IGHV mutational status (CXCL11\/I-TAC, CXCL10\/IP-10, sHEVM, and sLAG-3), were deciphered. These results pave the way to explore the role of soluble immune checkpoints as a promising source of biomarkers in CLL, to provide novel insights into the immune suppression process and\/or dysfunction, mostly on T cells, in combination with cellular balance disruption and microenvironment polarization leading to tumor escape.<\/jats:p>","DOI":"10.3389\/fimmu.2022.965905","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T06:50:52Z","timestamp":1664347852000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction"],"prefix":"10.3389","volume":"13","author":[{"given":"Alicia","family":"Landeira-Vi\u00f1uela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Arias-Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Juanes-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Navarro-Bail\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Pedreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Lecrevisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D\u00edaz-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"S\u00e1nchez-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela-Patricia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina L.","family":"Garc\u00eda-Vaquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"G\u00f3ngora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"De Las Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020524","article-title":"Clinico-biological implications of modified levels of cytokines in chronic lymphocytic leukemia: A possible therapeutic role","volume":"12","author":"Allegra","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02720","article-title":"Molecular interactions between innate and adaptive immune cells in chronic lymphocytic leukemia and their therapeutic implications","volume":"9","author":"Haseeb","year":"2018","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29747","article-title":"Evaluating the mechanism underlying antitumor effect of interleukin 27 on b cells of chronic lymphocytic leukemia patients","volume":"235","author":"Manouchehri-Doulabi","year":"2020","journal-title":"J Cell Physiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020217","article-title":"Nurse-like cells and chronic lymphocytic leukemia b cells: A mutualistic crosstalk inside tissue microenvironments","volume":"10","author":"Fiorcari","year":"2021","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/B978-0-323-47674-4.00099-2","article-title":"99 - chronic lymphocytic leukemia","volume-title":"Abeloff\u2019s clinical oncology","author":"Awan","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.74","article-title":"The prognostic significance of soluble NKG2D ligands in b-cell chronic lymphocytic leukemia","volume":"24","author":"N\u00fcckel","year":"2010","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01422","article-title":"Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: Direct contact, soluble factors, and extracellular vesicles","volume":"10","author":"Dubois","year":"2020","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153856","article-title":"Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia","volume":"13","author":"Vitale","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7484","article-title":"Intracellular IL-4 and IFN-\u03b3 expression in iNKT cells from patients with chronic lymphocytic leukemia","volume":"15","author":"Bojarska-Junak","year":"2018","journal-title":"Oncol Lett"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8820377","article-title":"Activating the antitumor immune response in non-Hodgkin lymphoma using immune checkpoint inhibitors","volume":"2020","author":"Joshi","year":"2020","journal-title":"J Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-467670","article-title":"IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells","volume":"122","author":"Pascutti","year":"2013","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.exphem.2018.01.003","article-title":"BTLA marks a less cytotoxic T-cell subset in diffuse large b-cell lymphoma with high expression of checkpoints","volume":"60","author":"Quan","year":"2018","journal-title":"Exp Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119150","article-title":"The role of CD47-SIRP\u03b1 immune checkpoint in tumor immune evasion and innate immunotherapy","volume":"273","author":"Li","year":"2021","journal-title":"Life Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00073","article-title":"Recent advances of tumor therapy based on the CD47-SIRP\u03b1 axis","volume":"19","author":"Wang","year":"2022","journal-title":"Mol Pharm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-030-36667-4_5","article-title":"The multifaceted roles of CXCL9 within the tumor microenvironment","volume":"1231","author":"Neo","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198:aid-cncr2820480131>3.0.co;2-v","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41598-020-60440-5","article-title":"Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma","volume":"10","author":"Dong","year":"2020","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005968","article-title":"Reactome graph database: Efficient access to complex pathway data","volume":"14","author":"Fabregat","year":"2018","journal-title":"PloS Comput Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1109\/TPAMI.2005.159","article-title":"Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy","volume":"27","author":"Peng","year":"2005","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1142\/s0219720005001004","article-title":"Minimum redundancy feature selection from microarray gene expression data","volume":"3","author":"Ding","year":"2005","journal-title":"J Bioinform Comput Biol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1007\/s10462-022-10275-5","article-title":"Recent advances in decision trees: An updated survey","author":"Costa","year":"2022","journal-title":"Artif Intell Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10462-011-9272-4","article-title":"Decision trees: A recent overview","volume":"39","author":"Kotsiantis","year":"2013","journal-title":"Artif Intell Rev"},{"key":"B30","article-title":"Cross-validatory choice and assessment of statistical predictions","volume":"36","author":"Stone","year":"1974","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092525","article-title":"Relevant cytokines in the b cell lymphoma micro-environment","volume":"12","author":"Krause","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-1185-6","article-title":"IL-4-dependent Jagged1 expression\/processing is associated with survival of chronic lymphocytic leukemia cells but not with notch activation","volume":"9","author":"De Falco","year":"2018","journal-title":"Cell Death Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071791","article-title":"Interleukin-1\u03b2 and cancer","volume":"12","author":"R\u00e9b\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","author":"Lemos","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200105)31:5<1428:AID-IMMU1428>3.0.CO;2-4","article-title":"ULBP1, 2, 3: Novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells","volume":"31","author":"Kubin","year":"2001","journal-title":"Eur J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010239","article-title":"Implication of soluble forms of cell adhesion molecules in infectious disease and tumor: Insights from transgenic animal models","volume":"19","author":"Ono","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002045","article-title":"CXCL9-expressing tumor-associated macrophages: New players in the fight against cancer","volume":"9","author":"Marcovecchio","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12731","article-title":"Potential clinical application of interleukin-27 as an antitumor agent","volume":"106","author":"Yoshimoto","year":"2015","journal-title":"Cancer Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adfm.202107540","article-title":"Immune cycle-based strategies for cancer immunotherapy","volume":"31","author":"Li","year":"2021","journal-title":"Adv Funct Mater"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.10.014","article-title":"2B4 and CD48: A powerful couple of the immune system","volume":"204","author":"Pahima","year":"2019","journal-title":"Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2016.01.008","article-title":"Roles of CD48 in regulating immunity and tolerance","volume":"164","author":"McArdel","year":"2016","journal-title":"Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2019.07.002","article-title":"TGF-\u03b2 regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression","volume":"224","author":"Huang","year":"2019","journal-title":"Immunobiology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0212","article-title":"The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia","volume":"6","author":"Nuebling","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29969","article-title":"Soluble b-cell activation marker of sCD27 and sCD30 and future risk of b-cell lymphomas: A nested case-control study and meta-analyses","volume":"138","author":"Hosnijeh","year":"2016","journal-title":"Int J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00537","article-title":"Tim-4 in health and disease: Friend or foe","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.965905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T22:02:10Z","timestamp":1676930530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.965905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2022.965905"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.965905","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"article-number":"965905"}}